The investigators observed no difference in mortality between BT alone and BT plus ADT and/or EBRT supplemental therapy.
In a study, the 17-year prostate cancer-specific and biochemical failure-free survival rates were 97% and 79%, respectively.
Physicians who treat patients with high-risk prostate cancer remain uncertain as to the optimal treatment approach, in part due to difficulty in interpreting study data.
Biochemical failure and prostate cancer-specific mortality rates were 13.3% and 4.9% at 10 years, respectively.
Androgen deprivation increased all-cause mortality risk by 77% among black men who underwent brachytherapy for favorable-risk prostate cancer.
TURP and EBRT after seed implantation are associated with development of urge urinary incontinence.
The increased risk occurs more than 10 years after treatment and most pronounced in men who undergo brachytherapy.
Potency is preserved in 50.4% and 60.8% of patients at 10 years after seed implantation, according to MSSFI and SHIM scores, respectively.
Findings based on 10-year follow-up of localized prostate cancer patients.
Combined radiotherapy remains controversial due to the increased potential for toxicities.
Researchers say they believe study findings support a hypothesis than ejaculation resulting from sexual intercourse might cause PSA bounce.
Study reveals comparable rates of freedom from biochemical failure at 5 years.
Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.
Prostate cancer patients undergoing radical prostatectomy increased by double digits while those undergoing brachytherapy decreased.
High rates of preserved sexual function with combination beam plus brachytherapy.
Study finds a 15-year cancer-specific survival rate of 94%; hormone therapy for more than 6 months decreases all-cause survival.
At 5 years after seed implantation, 59% prostate cancer patients had preserved erectile function.
PSA bounce was associated with significantly higher scores on the International Index of Erectile Function-15 questionnaire.
Use of this treatment for localized prostate cancer has been decreasing since 2002, perhaps due to increasing use of radical prostatectomy.
IMRT plus brachytherapy offers better PSA relapse-free and metastasis-free survival than high-dose IMRT alone.
In a study, the five-year biochemical failure-free survival rate was nearly 85%.
Researchers report good results using high-dose rather than low-dose interstitial brachytherapy.
By itself or combined with external beam radiation therapy, it offers excellent oncologic outcomes.
Modalities under investigation include laser ablation, hemiablative seed implantation, and results are promising.
Men with larger prostates are at higher risk for blood in urine.
Perineural invasion (PNI) and post-treatment PSA levels at 12 months strongly predict long-term PSA relapse-free survival (PRFS) after definitive brachytherapy seed implantation for prostate cancer (PCa), according to a study.
Brachytherapy appears to have significant advantages over EBRT in the treatment of men with low-risk and intermediate-risk prostate cancer.
Having performed more than 1,200 brachytherapy treatments, Michael F. Sarosdy, MD, is convinced that this is a far better choice than surgery.
PARIS—Cystoscopy prior to low dose rate (LDR) brachytherapy for prostate cancer is feasible and useful in identifying patients who require further investigation or intervention before seed implantation, researchers reported at the 27th Annual Congress of the European Association of Urology.
Noninvasive brachytherapy-like treatment may be a new option for men with prostate cancer.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)